鉴定一种靶向c-MYB的急性髓系白血病治疗药物
研究基于Connectivity Map数据库筛选出withaferin A(WFA),发现其可快速清除c-MYB蛋白并抑制c-MYB靶基因表达,降低白血病细胞活力、减少集落形成并损害疾病进展;WFA抗AML活性依赖c-MYB调节,可被稳定化c-MYB突变体部分逆转,机制涉及WFA诱导蛋白毒性和未折叠蛋白反应后破坏白血病细胞HSP/HSC70伴侣蛋白稳态。
要点
- WFA快速清除c-MYB蛋白并抑制c-MYB靶基因表达。
- WFA降低白血病细胞活力、减少集落形成并损害疾病进展。
- WFA抗AML活性依赖c-MYB调节,可被稳定化c-MYB突变体部分逆转。
核心结论
- WFA的抗AML活性依赖c-MYB调节,可被稳定化c-MYB突变体部分逆转。
- WFA在全球传统医学中广泛使用,表明其是将WFA重新用于AML治疗的有前景候选药物。
研究设计与样本
- 研究基于既往Connectivity Map数据库筛选结果,对另一命中化合物WFA进行功能验证。
主要发现
- WFA诱导c-MYB蛋白快速清除并抑制c-MYB靶基因表达。
- WFA导致白血病细胞活力丧失、集落形成减少和疾病进展受损。
- WFA抗AML活性依赖c-MYB调节,可被稳定化c-MYB突变体部分逆转。
- WFA诱导蛋白毒性和未折叠蛋白反应后破坏白血病细胞HSP/HSC70伴侣蛋白稳态,导致c-MYB清除。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A significant proportion of patients suffering from acute myeloid leukemia (AML) cannot be cured by conventional chemotherapy, relapsed disease being a common problem. Molecular targeting of essential oncogenic mediators is an attractive approach to improving outcomes for this disease. The hematopoietic transcription factor c-MYB has been revealed as a central component of complexes maintaining aberrant gene expression programs in AML. We have previously screened the Connectivity Map database to identify mebendazole as an anti-AML therapeutic targeting c-MYB. In the present study we demonstrate that another hit from this screen, the steroidal lactone withaferin A (WFA), induces rapid ablation of c-MYB protein and consequent inhibition of c-MYB target gene expression, loss of leukemia cell viability, reduced colony formation and impaired disease progression. Although WFA has been reported to have pleiotropic anti-cancer effects, we demonstrate that its anti-AML activity depends on c-MYB modulation and can be partially reversed by a stabilized c-MYB mutant. c-MYB ablation results from disrupted HSP/HSC70 chaperone protein homeostasis in leukemia cells following induction of proteotoxicity and the unfolded protein response by WFA. The widespread use of WFA in traditional medicines throughout the world indicates that it represents a promising candidate for repurposing into AML therapy.
引用
- Clesham K, Walf-Vorderwülbecke V, Gasparoli L, et al. Identification of a c-MYB-directed therapeutic for acute myeloid leukemia. Leukemia. 2022. PMID: 35368048. doi:10.1038/s41375-022-01554-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。